Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody

Edward R. Garrity*, Jaime Villanueva, Sangeeta M. Bhorade, Aliya N. Husain, Wickii T. Vigneswaran

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

65 Scopus citations


Background. The incidence and the severity of acute lung allograft rejection has been linked to the development of bronchiolitis obliterans syndrome. Therefore, we investigated the effects of daclizumab, a humanized monoclonal antibody directed against the alpha subunit of the interleukin 2 receptor, in reducing acute rejection after transplantation. Methods. We retrospectively evaluated 27 patients who received daclizumab as induction immunosuppression and compared them with a historical control group of 34 patients. Both groups received similar immunosuppressive regimens involving tacrolimus, prednisone, and either azathioprine or mycophenolate mofetil. All patients received cytomegalovirus and aspergillus prophylaxis. Results. Twenty-one patients in the control group and 22 patients in the daclizumab group were available for analysis at 6 months after lung transplantation. Ten (48%) patients in the control group had at least grade 2 acute rejection compared with four (18%) in the daclizumab group (P<0.04). The incidence of infection was similar in both groups. One patient in each group developed posttransplant lymphoproliferative disease. Conclusion. Therapy with daclizumab resulted in a significant decrease in the incidence of grade 2 or greater acute rejection after lung transplantation compared with historical controls. There seems to be no increase in the incidence of adverse effects in the patients treated with daclizumab.

Original languageEnglish (US)
Pages (from-to)773-777
Number of pages5
Issue number6
StatePublished - Mar 27 2001

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody'. Together they form a unique fingerprint.

Cite this